Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.

Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G, Wakeford C, Shaw A, Quinn J, Gish RG, Rousseau F.

J Infect Dis. 2005 Mar 15;191(6):825-9. Epub 2005 Feb 10.

PMID:
15717255
2.

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.

Martínez E, Blanco JL, Arnaiz JA, Pérez-Cuevas JB, Mocroft A, Cruceta A, Marcos MA, Milinkovic A, García-Viejo MA, Mallolas J, Carné X, Phillips A, Gatell JM.

AIDS. 2001 Jul 6;15(10):1261-8.

PMID:
11426070
3.

A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients.

Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL.

J Acquir Immune Defic Syndr. 2003 Sep;34 Suppl 1:S21-33.

PMID:
14562855
4.

Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors.

Guaraldi G, Squillace N, Stentarelli C, Orlando G, D'Amico R, Ligabue G, Fiocchi F, Zona S, Loria P, Esposito R, Palella F.

Clin Infect Dis. 2008 Jul 15;47(2):250-7. doi: 10.1086/589294.

PMID:
18532884
5.

Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program.

Idigbe EO, Adewole TA, Eisen G, Kanki P, Odunukwe NN, Onwujekwe DI, Audu RA, Araoyinbo ID, Onyewuche JI, Salu OB, Adedoyin JA, Musa AZ.

J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):65-9.

PMID:
16123684
6.

[Cutaneous drug-reactions to nevirapine: study of risk factors in 101 HIV-infected patients].

Pitche P, Drobacheff-Thiebaut C, Gavignet B, Mercier M, Laurent R.

Ann Dermatol Venereol. 2005 Dec;132(12 Pt 1):970-4. French.

PMID:
16446639
7.

Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.

Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W.

Clin Infect Dis. 2007 Feb 1;44(3):447-52. Epub 2006 Dec 27.

PMID:
17205457
8.

A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.

Arranz Caso JA, López JC, Santos I, Estrada V, Castilla V, Sanz J, Sanz J, Molina JP, Fernández Guerrero M, Górgolas M.

HIV Med. 2005 Sep;6(5):353-9. Erratum in: HIV Med. 2005 Nov;6(6):426.

9.

Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients.

Torti C, Costarelli S, De Silvestri A, Quiros-Roldan E, Lapadula G, Cologni G, Paraninfo G, Castelnuovo F, Puoti M, Carosi G; BHCC Study Group.

Drug Saf. 2007;30(12):1161-9.

PMID:
18035868
10.

No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors.

Dailly E, Billaud E, Reliquet V, Breurec S, Perré P, Léautez S, Jolliet P, Bourin M, Raffi F.

Eur J Clin Pharmacol. 2004 Jul;60(5):343-8. Epub 2004 May 20.

PMID:
15156302
11.

Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients.

Reliquet V, Ferré V, Hascoet C, Besnier JM, Bellein V, Arvieux C, Molina JM, Breux JP, Zucman D, Rozenbaum W, Allavena C, Raffi F; VIRGO Study Team.

Antivir Ther. 1999;4 Suppl 3:83-4.

PMID:
16021876
12.

High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.

Rey D, Hoen B, Chavanet P, Schmitt MP, Hoizey G, Meyer P, Peytavin G, Spire B, Allavena C, Diemer M, May T, Schmit JL, Duong M, Calvez V, Lang JM.

J Antimicrob Chemother. 2009 Feb;63(2):380-8. doi: 10.1093/jac/dkn471. Epub 2008 Nov 25.

PMID:
19036752
13.

Long-term safety and efficacy of nevirapine, stavudine and lamivudine in a real-world setting.

Shalit P, Farrell P, Lindgren P.

AIDS. 2001 Apr 13;15(6):804-5. No abstract available.

PMID:
11371699
15.

Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women.

Marazzi MC, Germano P, Liotta G, Guidotti G, Loureiro S, da Cruz Gomes A, Valls Blazquez MC, Narciso P, Perno CF, Mancinelli S, Palombi L.

HIV Med. 2006 Jul;7(5):338-44.

16.

Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.

Jones R, Sawleshwarkar S, Michailidis C, Jackson A, Mandalia S, Stebbing J, Bower M, Nelson M, Gazzard BG, Moyle GJ.

HIV Med. 2005 Nov;6(6):396-402.

17.

Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy.

Kamya MR, Mayanja-Kizza H, Kambugu A, Bakeera-Kitaka S, Semitala F, Mwebaze-Songa P, Castelnuovo B, Schaefer P, Spacek LA, Gasasira AF, Katabira E, Colebunders R, Quinn TC, Ronald A, Thomas DL, Kekitiinwa A; Academic Alliance for AIDS Care and Prevention in Africa.

J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):187-93.

PMID:
17693883
18.

A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity.

Kumar PN, Rodriguez-French A, Thompson MA, Tashima KT, Averitt D, Wannamaker PG, Williams VC, Shaefer MS, Pakes GE, Pappa KA; ESS40002 Study Team.

HIV Med. 2006 Mar;7(2):85-98.

19.

Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.

Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Saekang N, Pairoj W, Chantratita W.

J Clin Virol. 2008 Apr;41(4):310-3. doi: 10.1016/j.jcv.2007.12.015. Epub 2008 Mar 7.

PMID:
18316243
20.

Liver toxicity caused by nevirapine.

González de Requena D, Núñez M, Jiménez-Nácher I, Soriano V.

AIDS. 2002 Jan 25;16(2):290-1.

PMID:
11807315

Supplemental Content

Support Center